Omeros Corp
OMER6.590USD
+0.010+0.15%
Handelsschluss 11/07, 16:00（ET）Kurse um 15 Minuten verzögert
395.55MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Omeros Corp Unternehmen
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Omeros Corp Informationen
BörsenkürzelOMER
Name des UnternehmensOmeros Corp
IPO-datumOct 08, 2009
CEODR. Gregory A. Demopulos, M.D.
Anzahl der mitarbeiter202
WertpapierartOrdinary Share
GeschäftsjahresendeOct 08
Addresse201 Elliott Avenue West
StadtSEATTLE
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl98119
Telefon12066765000
Websitehttps://www.omeros.com/
BörsenkürzelOMER
IPO-datumOct 08, 2009
CEODR. Gregory A. Demopulos, M.D.
Führungskräfte von Omeros Corp
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Peter A. Demopulos, M.D.
Dr. Peter A. Demopulos, M.D.
Director
Director
372.90K
--
Dr. Leroy E. Hood, M.D., Ph.D.
Dr. Leroy E. Hood, M.D., Ph.D.
Independent Director
Independent Director
74.39K
--
Mr. Thomas J. Cable
Mr. Thomas J. Cable
Lead Independent Director
Lead Independent Director
35.07K
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
12.40K
--
Dr. Mariana N. Dimitrova, Ph.D.
Dr. Mariana N. Dimitrova, Ph.D.
Vice President - Chemistry, Manufacturing and Controls
Vice President - Chemistry, Manufacturing and Controls
--
--
Mr. Peter B. Cancelmo, J.D.
Mr. Peter B. Cancelmo, J.D.
Vice President, General Counsel, Secretary
Vice President, General Counsel, Secretary
--
--
Dr. Thomas F. Bumol, Ph.D.
Dr. Thomas F. Bumol, Ph.D.
Independent Director
Independent Director
--
--
Dr. Catherine A. Melfi, Ph.D.
Dr. Catherine A. Melfi, Ph.D.
Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
--
--
DR. Gregory A. Demopulos, M.D.
DR. Gregory A. Demopulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. David J. Borges
Mr. David J. Borges
Chief Accounting Officer, Vice President - Finance, Treasurer
Chief Accounting Officer, Vice President - Finance, Treasurer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Peter A. Demopulos, M.D.
Dr. Peter A. Demopulos, M.D.
Director
Director
372.90K
--
Dr. Leroy E. Hood, M.D., Ph.D.
Dr. Leroy E. Hood, M.D., Ph.D.
Independent Director
Independent Director
74.39K
--
Mr. Thomas J. Cable
Mr. Thomas J. Cable
Lead Independent Director
Lead Independent Director
35.07K
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
12.40K
--
Dr. Mariana N. Dimitrova, Ph.D.
Dr. Mariana N. Dimitrova, Ph.D.
Vice President - Chemistry, Manufacturing and Controls
Vice President - Chemistry, Manufacturing and Controls
--
--
Mr. Peter B. Cancelmo, J.D.
Mr. Peter B. Cancelmo, J.D.
Vice President, General Counsel, Secretary
Vice President, General Counsel, Secretary
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Nov 8
Aktualisiert: Sat, Nov 8
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Ingalls & Snyder LLC (Asset Management)
6.03%
BlackRock Institutional Trust Company, N.A.
5.43%
The Vanguard Group, Inc.
4.92%
D. E. Shaw & Co., L.P.
2.42%
Stifel, Nicolaus & Company, Incorporated
2.24%
Andere
78.96%
Aktionäre
Aktionäre
Anteil
Ingalls & Snyder LLC (Asset Management)
6.03%
BlackRock Institutional Trust Company, N.A.
5.43%
The Vanguard Group, Inc.
4.92%
D. E. Shaw & Co., L.P.
2.42%
Stifel, Nicolaus & Company, Incorporated
2.24%
Andere
78.96%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
16.48%
Investment Advisor
15.58%
Hedge Fund
6.07%
Research Firm
3.82%
Individual Investor
2.90%
Bank and Trust
0.88%
Insurance Company
0.12%
Venture Capital
0.09%
Pension Fund
0.05%
Andere
53.99%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
243
29.83M
43.83%
+1.23M
2025Q2
255
30.16M
44.94%
-422.08K
2025Q1
263
30.38M
51.89%
-522.27K
2024Q4
256
29.32M
50.59%
-441.66K
2024Q3
242
27.89M
48.13%
-1.92M
2024Q2
248
27.65M
47.72%
-3.10M
2024Q1
269
28.11M
48.16%
-3.03M
2023Q4
275
27.52M
43.79%
-6.21M
2023Q3
299
30.25M
48.14%
-4.77M
2023Q2
303
29.52M
46.99%
+306.67K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Ingalls & Snyder LLC (Asset Management)
3.98M
5.85%
+5.10K
+0.13%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.69M
5.43%
-328.94K
-8.18%
Jun 30, 2025
The Vanguard Group, Inc.
3.28M
4.82%
+46.32K
+1.43%
Jun 30, 2025
D. E. Shaw & Co., L.P.
1.65M
2.42%
-291.10K
-15.02%
Jun 30, 2025
Stifel, Nicolaus & Company, Incorporated
1.52M
2.24%
-33.76K
-2.17%
Jun 30, 2025
Demopulos (Gregory A. M.D.)
2.03M
2.98%
--
--
May 23, 2025
Geode Capital Management, L.L.C.
1.37M
2.01%
+739.00
+0.05%
Jun 30, 2025
State Street Investment Management (US)
1.20M
1.76%
-156.01K
-11.50%
Jun 30, 2025
Two Sigma Investments, LP
1.09M
1.61%
+971.88K
+802.28%
Jun 30, 2025
Morgan Stanley & Co. LLC
1.09M
1.6%
+501.25K
+85.73%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Thu, Nov 6
Aktualisiert: Thu, Nov 6
Name
Anteil
Invesco NASDAQ Future Gen 200 ETF
0.48%
iShares Micro-Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Mehr Anzeigen
Invesco NASDAQ Future Gen 200 ETF
Anteil0.48%
iShares Micro-Cap ETF
Anteil0.05%
Invesco Nasdaq Biotechnology ETF
Anteil0.03%
ProShares Ultra Nasdaq Biotechnology
Anteil0.03%
ProShares UltraPro Russell2000
Anteil0.01%
iShares Russell 2000 ETF
Anteil0.01%
Invesco RAFI US 1500 Small-Mid ETF
Anteil0.01%
Proshares Ultra Russell 2000
Anteil0.01%
ProShares Hedge Replication ETF
Anteil0.01%
iShares Russell 2000 Growth ETF
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
